Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929669 · ClinicalTrials.gov registry record · Phase 2
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00929669: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT00929669 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929669, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.
Primary Outcome
MRI of the pituitary will be performed at baseline, Month 6 and Month 12 to demonstrate a decrease of ≥3 mm in at least two of three dimensions on MRI (cephalocaudal, transverse, and posterior-anterior). The outcome measure is defined as the number of participants who demonstrated a ≥3 mm decrease in adenoma size in two dimensions.
Interventions
- DRUG pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Why NCT00929669 stopped before completion
NCT00929669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which pasireotide LAR is the first listed.
NCT00929669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00929669 about?
NCT00929669 is a clinical study titled "Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas". The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.
What is the current status of trial NCT00929669?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00929669?
The interventions under investigation include: pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT00929669?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00929669's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia